Table 1.
Baseline characteristics of the regdanvimab and supportive care groups.
| Variables | Regdanvimab | Supportive care | P value |
|---|---|---|---|
| (n = 234) | (n = 544) | ||
| Demographics | |||
| Age, years | 51.8 ± 14.3 | 56.2 ± 15.3 | <0.001 |
| Male sex | 130 (55.6) | 267 (49.1) | 0.101 |
| BMI | 25.2 ± 3.6 | 24.8 ± 3.6 | 0.112 |
| Sx onset to admission, days | 2.8 ± 2.0 | 3.5 ± 2.2 | <0.001 |
| Initial presentation | |||
| Initial Ct value (NP swab, RdRp) | 19.2 ± 6.4 | 19.9 ± 5.7 | 0.160 |
| Pneumonia | 168 (71.8) | 354 (65.1) | 0.068 |
| SIRS | 47 (20.1) | 95 (17.5) | 0.418 |
| SpO2 | 97.2 ± 1.0 | 97.3 ± 1.2 | 0.748 |
| Initial laboratory tests | |||
| WBC count,/μL | 4749.4 ± 1505.4 | 4812.3 ± 1535.9 | 0.599 |
| Lymphocyte count,/μL | 1202.1 ± 460.9 | 1264.3 ± 720.8 | 0.224 |
| Platelet count, x103/μL | 199.7 ± 61.3 | 191.8 ± 66.0 | 0.116 |
| Total bilirubin, mg/dL | 0.62 ± 0.3 | 0.59 ± 0.2 | 0.155 |
| Albumin, g/dL | 4.5 ± 0.3 | 4.4 ± 0.3 | 0.002 |
| AST, IU/L | 32.7 ± 18.5 | 33.3 ± 19.6 | 0.704 |
| ALT, IU/L | 33.7 ± 23.6 | 32.9 ± 24.9 | 0.668 |
| BUN, mg/dL | 13.5 ± 4.0 | 14.4 ± 4.9 | 0.004 |
| Creatinine, mg/dL | 0.8 ± 0.2 | 0.9 ± 0.3 | 0.287 |
| CPK, IU/L | 128.3 ± 185.7 | 127.5 ± 165.2 | 0.953 |
| LDH, IU/L | 388.7 ± 100.9 | 398.0 ± 121.3 | 0.265 |
| CRP, mg/dL | 1.2 ± 1.7 | 1.7 ± 2.9 | 0.001 |
| Underlying diseases* | |||
| Cardiovascular disease | 22 (9.4) | 54 (9.9) | 0.896 |
| Respiratory disease | 8 (3.4) | 35 (6.4) | 0.122 |
| Diabetes mellitus | 40 (17.1) | 91 (16.7) | 0.917 |
| Hypertension | 79 (33.8) | 182 (33.5) | 0.934 |
| Liver disease | 4 (1.7) | 7 (1.3) | 0.647 |
| Renal disease | 1 (0.4) | 3 (0.6) | 0.824 |
| Charlson Comorbidity Index | 0 (0–1) | 0 (0–1) | 0.176 |
Data are expressed as the number (%) of patients, mean ± SD, or median (IQR) unless indicated otherwise. *There were no immunocompromised patients, such as hematology/oncology patients, organ transplant recipients, or HIV-infected patients.
BMI, body mass index; Sx, symptom; Ct, cycle threshold; NP, nasopharyngeal; RdRp, RNA-dependent RNA polymerase; SIRS, systemic inflammatory response syndrome; SpO2, saturation of percutaneous oxygen; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; CPK, creatine phosphokinase; LDH, lactate dehydrogenase; CRP, C-reactive protein; HIV, human immunodeficiency virus.